Yamaguchi Naoki, Kobayashi Keiko, Yasuda Tomotsugu, Nishi Ikumi, Iijima Mikio, Nakagawa Masanori, Osame Mitsuhiro, Kondo Ikuko, Saheki Takeyori
Department of Biochemistry, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
Hum Mutat. 2002 Feb;19(2):122-30. doi: 10.1002/humu.10022.
We have recently identified SLC25A13 on chromosome 7q21.3 as the gene responsible for adult-onset type II citrullinemia (CTLN2) and found seven mutations in the SLC25A13 gene of CTLN2 patients. Most recently, the SLC25A13 mutations have been detected in neonatal/infantile patients with a type of neonatal hepatitis associated with cholestasis (NICCD). In the present study, we identified a novel mutation, E601X, in the SLC25A13 gene and established multiple DNA diagnosis methods for eight mutations by using a genetic analyzer with GeneScan and the single primer extension procedure (SNaPshot). An additional novel missense mutation (variation), E601K, was detected by SNaPshot analysis and was indistinguishable from the mutation E601X detected by the PCR/RFLP method. Multiple DNA diagnoses for the nine mutations revealed that 100 (male/female: 70/30) out of 115 CTLN2 and 38 (14/24) out of 45 NICCD patients tested were homozygotes or compound heterozygotes. The frequency of homozygotes carrying SLC25A13 mutations in both alleles is estimated to be minimally 1 in 21,000 from carrier detection (18 in 1,315 individuals tested) in the Japanese population. The differences in the gender ratio and in mutation types between CTLN2 and NICCD patients are significant. It is, however, unknown whether all homozygotes with mutated SLC25A13 in both alleles suffer from NICCD, CTLN2, both, or neither.
我们最近确定位于7号染色体q21.3区域的SLC25A13基因是成人II型瓜氨酸血症(CTLN2)的致病基因,并在CTLN2患者的SLC25A13基因中发现了7个突变。最近,在患有与胆汁淤积相关的新生儿肝炎(NICCD)的新生儿/婴儿患者中检测到了SLC25A13突变。在本研究中,我们在SLC25A13基因中鉴定出一个新的突变E601X,并使用带有GeneScan的基因分析仪和单引物延伸程序(SNaPshot)建立了针对8种突变的多种DNA诊断方法。通过SNaPshot分析检测到另一个新的错义突变(变异)E601K,它与通过PCR/RFLP方法检测到的突变E601X无法区分。对这9种突变的多种DNA诊断显示,在接受检测的115例CTLN2患者中有100例(男/女:70/30)以及45例NICCD患者中有38例(14/24)为纯合子或复合杂合子。根据日本人群中携带者检测结果(在1315例受检个体中有18例)估计,两个等位基因均携带SLC25A13突变的纯合子频率至少为21000分之一。CTLN2患者和NICCD患者在性别比例和突变类型上的差异具有显著性。然而,尚不清楚两个等位基因的SLC25A13均发生突变的所有纯合子是否患有NICCD、CTLN2、两者皆有或两者皆无。